| 研究開始時の研究の概要 |
In this study we carried out a well-designed CRISPR screening in which we transduced the cells with PD-L1-3’UTR. In this case, we can find out the RNA-binding proteins which can directly decay PD-L1 mRNA, which so far remains elusive. We will investigate the underlying mechanism of how the candidate RBP delays PD-L1 mRNA, and provide new insights into regulation of RBPs in anti-tumor immunity. So far, clinical research has proven that only few strategies may be efficient in reducing PD-L1.We will provide a novel therapeutic strategyto promote the efficacy of immunotherapy to tumor patients.
|
